The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed?
Event Description
Maintenance therapy remains standard for most myeloma patients in today's treatment landscape. How has that changed throughout myeloma treatment history and what could the future of maintenance therapy look like? We look forward to hearing Dr. Sam Rubinstein's thoughts on the subject.
Schedule & Agenda
Marisol introduces the agenda of the event and featured speaker Dr. Sam Rubinstein.
Marisol introduces the agenda of the event and featured speaker Dr. Sam Rubinstein.
Dr. Sam Rubinstein shares his thoughts on maintenance therapy.
Dr. Sam Rubinstein shares his thoughts on maintenance therapy.
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators
Soy la Coordinadora de Eventos en la fundación de HealthTree. En conjunto con la Directora de Eventos trabajamos para traer reuniones de diferentes temas de interés para los pacientes. Nuestra misión es hacer llegar nuestro programa a más gente, tanto en inglés como en español.
Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Get the latest thought leadership on your Chronic Myeloid Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.